US › Healthcare

Sagimet Biosciences Inc. Series A Common Stock (SGMT)

US · Healthcare · Biotechnology

$7.99+11.75%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-10.7M
Profit YoY
+41.4%
EPS
$-0.33
EPS estimate
$-0.35

EPS came in at -0.33 against a street estimate of -0.35 — a beat of 5.7%.

Key statistics

Market cap
$439.1M
Forward P/E
0.0
P/B
4.29
Book value
$3.14
EPS (TTM)
$-1.35
52-week high
$10.06
52-week low
$4.50
50-day MA
$7.12
200-day MA
$6.58
Beta
3.38

Analyst view

Analysts rate Sagimet Biosciences Inc. Series A Common Stock a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $26.20.

Shareholding

Insiders
3.37%
Institutions
24.18%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC1.78%
Woodline Partners LP1.62%
Marshall Wace Asset Management Ltd1.56%
Baker Bros Advisors LP1.54%
Affinity Asset Advisors, LLC1.41%
Millennium Management LLC1.40%
BlackRock Inc1.30%
Hillhouse Capital Advisors, Ltd.1.17%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sagimet Biosciences Inc. Series A Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.